Verastem (Nasdaq:VSTM) - Aandelenkoers, Nieuws & Analyse

VSTM Overzicht aandelen

Verastem, Inc., een biofarmaceutisch bedrijf in een ontwikkelingsstadium, richt zich op de ontwikkeling en commercialisering van geneesmiddelen voor de behandeling van kanker in de Verenigde Staten.

Over het bedrijf

VSTM fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Revenue is forecast to grow 57.09% per year

Risicoanalyse

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the US market

Verastem, Inc. Concurrenten

Cibus

NasdaqCM:CBUS

US$126.5m

I-Mab

NasdaqGM:IMAB

US$87.1m

uniQure

NasdaqGS:QURE

US$285.4m

Sage Therapeutics

NasdaqGM:SAGE

US$370.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Verastem
Historische aandelenkoersen
Huidige aandelenkoers	US$3.92
52 Week Hoogtepunt	US$14.22
52 Week Laag	US$2.10
Bèta	0.16
11 maand verandering	36.59%
3 maanden verandering	67.52%
1 Jaar Verandering	-40.79%
33 jaar verandering	-88.25%
5 jaar verandering	-69.75%
Verandering sinds IPO	-97.05%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	VSTM	US Biotechs	US Markt
7D	15.6%	-0.7%	-1.6%
1Y	-40.8%	19.8%	30.8%

Rendement versus industrie: VSTM underperformed the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: VSTM underperformed the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is VSTM's price volatile compared to industry and market?
VSTM volatility
VSTM Average Weekly Movement	12.9%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: VSTM's share price has been volatile over the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: VSTM's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2010	73	Dan Paterson	www.verastem.com

Verastem, Inc., een biofarmaceutisch bedrijf in een ontwikkelingsstadium, richt zich op de ontwikkeling en commercialisering van geneesmiddelen voor de behandeling van kanker in de Verenigde Staten. Haar productkandidaten zijn Avutometinib, een oraal verkrijgbare kleine molecule RAF/MEK-klem die de RAF/MEK-, ERK mitogen activated pathway kinase-routine remt die betrokken is bij celproliferatie, migratie, transformatie en overleving van tumorcellen; en Defactinib, een orale kleine molecule remmer van FAK en proline-rijke tyrosinekinase voor verschillende vaste tumoren. Het bedrijf is betrokken bij klinische studies, waaronder RAMP 301, een gerandomiseerde wereldwijde bevestigende studie om de combinatie van Avutometinib en Defactinib te evalueren voor de behandeling van patiënten met terugkerende laaggradige sereuze eierstokkanker; RAMP 201, een adaptieve tweedelige multicenter, parallel cohort, gerandomiseerde open-label studie ter evaluatie van de werkzaamheid en veiligheid van Avutometinib en in combinatie met Defactinib; en FRAME, een onderzoek naar Avutometinib en Defactinib bij patiënten met KRAS-mutant kankers en daaropvolgende analyses; en RAMP 204 en 205.

Verastem, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Verastem zich tot de beurswaarde?
VSTM fundamentele statistieken
Marktkapitalisatie	US$157.76m
Inkomsten(TTM)	-US$89.49m
Inkomsten(TTM)	US$10.00m

15.8x

P/S-verhouding

-1.8x

Koers/Winstverhouding

Is VSTM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
VSTM resultatenrekening (TTM)
Inkomsten	US$10.00m
Kosten van inkomsten	US$0
Brutowinst	US$10.00m
Overige uitgaven	US$99.49m
Inkomsten	-US$89.49m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.22
Brutomarge	100.00%
Nettowinstmarge	-894.91%
Schuld/Eigen Vermogen Verhouding	102.1%

Hoe presteerde VSTM op de lange termijn?

Bekijk historische prestaties en vergelijking

VSTM Overzicht aandelen

Beloningen

Risicoanalyse

Verastem, Inc. Concurrenten

NasdaqCM:CBUS

US$126.5m

NasdaqGM:IMAB

US$87.1m

NasdaqGS:QURE

US$285.4m

NasdaqGM:SAGE

US$370.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as A Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem Oncology Announces First Patient Dosed with Gfh375/Vs-7375 in A Phase 1/2 Trial in China as Part of Collaboration with Genfleet Therapeutics

Recent updates

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as A Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem Oncology Announces First Patient Dosed with Gfh375/Vs-7375 in A Phase 1/2 Trial in China as Part of Collaboration with Genfleet Therapeutics

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces the Launch of the New Healthcare Professional Component

Verastem, Inc. has filed a Follow-on Equity Offering in the amount of $6.510455 million.

Verastem Oncology Announces Executive Appointments

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $85.018462 million.

Verastem Oncology Announces 1-for-12 Reverse Stock Split to Satisfy the Price Requirement for Continued Listing on the Nasdaq Global Market

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Price target decreased by 9.3% to US$3.25

Price target decreased by 11% to US$3.79

Verastem, Inc. announced that it expects to receive $59.995963 million in funding from BVF Partners L.P.

Price target decreased by 8.5% to US$4.30

Verastem, Inc. announced that it expects to receive $60 million in funding

Verastem Oncology Appoints Rob Gagnon to the Board of Directors

Less than half of directors are independent

Consensus forecasts updated

Price target decreased to US$4.70

Price target decreased to US$4.75

Verastem Oncology Appoints Anil Kapur to Board of Directors

Verastem Oncology Announces RAMP VS-6766 Clinical Trials

Verastem: Moving Forward

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Second quarter 2022 earnings released: US$0.12 loss per share (vs US$0.098 loss in 2Q 2021)

Verastem Non-GAAP EPS of -$0.11 in-line

Verastem: Looking Increasingly Attractive

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 2000 Dynamic Index

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$5.40

Less than half of directors are independent

Verastem: Time To Take My Position Out Of Mothball

Price target decreased to US$5.50

Consensus forecasts updated

Verastem, Inc., Annual General Meeting, May 12, 2022

Less than half of directors are independent

No longer forecast to breakeven

Verastem, Inc. Announces Management Changes

Vectoring In On Verastem

CEO & Director recently sold US$53k worth of stock

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.078 profit in 3Q 2020)

Verastem: Buying Opportunity Following Unjustified Sell-Off

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

Consensus forecasts updated